Cencora inc(COR.US AI Earnings Summary)
COR AI Earnings Summary (In-Depth)
2026 Q4 (Fiscal Year)
Core Highlights
- Stock Price Reaction: CENCORA INC announced its earnings on November 4, 2026. Benefiting from strong demand for specialty pharmaceuticals and M&A synergies, adjusted EPS and revenue performance were impressive. The stock closed at $354.00 on 11/4, up 3.96% from the 11/3 close of $340.50.
- Market Expectations: No market expectations comparison data available; no magnitude determination or cause analysis performed.
- Performance vs. Previous Guidance: All targets met or exceeded. Full-year adjusted diluted EPS of $17.97 was approximately 0.1% above the upper bound of guidance. Full-year adjusted operating income growth of 14% fell near the upper bound of the guidance range. Adjusted free cash flow of approximately $3.8B was higher than guidance.
- In a Nutshell: COR leveraged strong demand for specialty drugs and the OneOncology acquisition to exceed all full-year profit and cash flow guidance, with the market responding as the stock closed up 3.96% at $354.00 on 11/4.
Quarterly Highlights
Record full-year and quarterly results as OneOncology acquisition benefits fully materialize, driving a 22% YoY increase in adjusted operating income this quarter.
Full-year adjusted diluted EPS reached $17.97, exceeding the upper bound of internal expectations: Fiscal year 2026 full-year adjusted diluted EPS was $17.97, up 12% YoY, higher than the $17.95 upper limit of the guidance provided last quarter. Full-year adjusted operating income grew 14%, landing near the upper end of the internal expectation range, a record high for several consecutive years.
Quarterly adjusted diluted EPS up 21% YoY to $4.66, the strongest quarter of the year: Fiscal year 2026 fourth quarter (hereafter referred to as "this quarter") adjusted diluted EPS reached $4.66, up 21% YoY, benefiting from OneOncology's contribution, continued growth in specialty drug volume, and an easier expense comparison base. This quarter was also the fastest-growing quarter for adjusted operating income among the four quarters of the year.
U.S. Healthcare Solutions segment operating income up 22% YoY, the strongest quarter of the fiscal year: This quarter, the U.S. Healthcare Solutions segment's adjusted operating income reached $998M, up 22% YoY. The operating margin expanded from 1.10% in the same period last year to 1.27%. Growth momentum came from specialty drug sales to health systems and physician practices, OneOncology contributions, and an easier expense comparison base.
GLP-1 drugs (diabetes and weight management) up $2.8B YoY, becoming a key growth engine for the U.S. segment: In this quarter, U.S. segment sales of GLP-1 drugs increased by $2.8B compared to the same period last year. Simultaneously, manufacturer price reductions (WAC decreases) created a $2.8B revenue headwind, largely offsetting the sales gain. However, GLP-1 volume growth remains positive for the overall profit structure.
Adjusted gross margin expanded 57 bps QoQ to 4.04%, with OneOncology as the primary driver: Consolidated adjusted gross profit this quarter reached $3.6B, up 23% YoY. Gross margin increased by 57 basis points YoY to 4.04%, primarily due to the high-margin specialty business brought in by the OneOncology acquisition completed in February 2026. Excluding OneOncology and Retina Consultants of America (RCA), operating expense growth was below 3%, demonstrating solid core expense control.
International Healthcare Solutions segment constant currency operating income up 19% YoY, with strong performance in Canada and Global Specialty Logistics: International segment revenue was $7.8B, up 5% YoY (approx. 8% at constant currency). Adjusted operating income was $152M, up 16% YoY (19% at constant currency). CFO Eva Boratto noted that the Canadian business performed exceptionally well driven by high program win rates, while Global Specialty Logistics and Third-Party Logistics (3PL) businesses maintained double-digit operating income growth.
Full-year adjusted free cash flow reached $3.8B, significantly exceeding the internal expectation of approx. $3.0B: Fiscal year 2026 full-year adjusted free cash flow (FCF) was approximately $3.8B, significantly higher than the roughly $3.0B guidance provided last quarter, benefiting from stronger year-end sales volume, better product mix (selling more high-margin products), and timing factors. The year-end cash balance reached $4.9B.
Major organizational restructuring announced, creating two new reporting segments to enhance specialty platform visibility: Cencora announced a reorganization of its reporting structure into two new segments: "Specialty Physician Services" and "Pharmaceutical Distribution and Services." Long-term operating income growth targets were also announced—approx. 14%–16% for the former and mid-single digits for the latter. CEO Bob Mauch stated this move integrates all specialty service assets under a single leader, helping to accelerate innovation and improve transparency for shareholders.
Acquisition of majority stake in American Oncology Network announced, MSO platform continues to expand: Cencora agreed to acquire a majority stake in American Oncology Network (AON), a physician-led network with over 350 providers across 21 states, serving as a significant extension to the existing OneOncology and RCA platforms. The Management Services Organization (MSO) platform contributed approximately 10% of total corporate adjusted operating income for the full fiscal year 2026.